HR 6482
116th Congress
House
Health
Asia
Business expenses
China
Drug safety, medical device, and laboratory regulation
Government information and archives
Health care costs and insurance
Health programs administration and funding
Health technology, devices, supplies
Income tax deductions
Manufacturing
Military medicine
Military procurement, research, weapons development
Prescription drugs
Public contracts and procurement
Trade restrictions
Veterans' medical care
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
Introduced: April 10, 2020
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 13, 2020
Referred to the Subcommittee on Oversight and Investigations.
Apr 10, 2020
Referred to the Subcommittee on Health.
Apr 10, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 10, 2020
Introduced in House
Plain-English summary
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
What's happening now
Referred to the Subcommittee on Oversight and Investigations.